JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2007; 49:1722-1732, doi:10.1016/j.jacc.2007.01.064 (Published online 4 April 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2007.01.064v1
49/16/1722    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mochizuki, M.
Right arrow Articles by Matsuzaki, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mochizuki, M.
Right arrow Articles by Matsuzaki, M.

PRECLINICAL STUDY

Scavenging Free Radicals by Low-Dose Carvedilol Prevents Redox-Dependent Ca2+ Leak Via Stabilization of Ryanodine Receptor in Heart Failure

Mamoru Mochizuki, MD*,1, Masafumi Yano, MD, PhD*,1,*, Tetsuro Oda, MD, PhD*, Hiroki Tateishi, MD*, Shigeki Kobayashi, MD, PhD*, Takeshi Yamamoto, MD, PhD*, Yasuhiro Ikeda, MD, PhD*, Tomoko Ohkusa, MD, PhD*, Noriaki Ikemoto, PhD{dagger},{ddagger} and Masunori Matsuzaki, MD, PhD, FACC*

* Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, Ube, Japan
{dagger} Boston Biomedical Research Institute, Watertown, Massachusetts
{ddagger} Department of Neurology, Harvard Medical School, Boston, Massachusetts.

Manuscript received June 12, 2006; revised manuscript received December 11, 2006, accepted January 1, 2007.

* Reprint requests and correspondence: Dr. Masafumi Yano, Department of Medicine and Clinical Science, Division of Cardiology, Yamaguchi University Graduate School of Medicine, 1-1-1 Minamikogushi, Ube, Yamaguchi, 755-8505, Japan. (Email: yanoma{at}yamaguchi-u.ac.jp).

Objectives: We investigated whether defective intracellular Ca2+ handling is corrected by carvedilol in heart failure.

Background: In heart failure, the interaction between the N-terminal and central domains of the ryanodine receptor (RyR), the domains where many mutations have been found in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), is defective, as shown in our recent report.

Methods: Sarcoplasmic reticulum vesicles were isolated from canine left ventricular muscle (normal or 4-weeks rapid ventricular pacing). The RyR was labeled with the fluorescent conformational probe methylcoumarin acetate (MCA) with DPc10 (a synthetic peptide corresponding to Gly2460-Pro2495 of RyR, one of the mutable domains in CPVT) as a site-direction carrier.

Results: Normal cardiac function was well preserved in carvedilol-treated/paced dogs (CV+) but not in the untreated/paced dogs (CV–). In CV–, the interdomain interaction within RyR was defective (i.e., in an unzipped state), as determined by the fluorescence quenching technique. However, in CV+, the domain interaction remained normal (i.e., in a zipped state). In CV–, oxidative stress of RyR (reduction in the number of free thiols) was severe, but it was negligible in CV+. In (CV–) failing cardiomyocytes, incubation with low-dose CV (30 nmol/l), which eliminated intracellular reactive oxygen species with no acute effect on cell shortening, markedly improved the contractile function and Ca2+ transient. However, after domain unzipping by DPc10, CV was without effect.

Conclusions: Carvedilol, at a concentration that is sufficient to produce antioxidant effect, improves the intracellular Ca2+ handling and contractile dysfunction by correcting defective interdomain interaction within the RyR in the failing heart.

Abbreviations and Acronyms
  CPVT = catecholaminergic polymorphic ventricular tachycardia
  CV = carvedilol
  DCFH-DA = 2',7'-dichlorofluorescin diacetate
  DPc10 = a synthetic peptide corresponding to Gly2460-Pro2495 of ryanodine receptor
  LV = left ventricle/ventricular
  mBB = monobromobimane
  MCA = methylcoumarin acetate
  PKA = protein kinase A
  PLB = phospholamban
  ROS = reactive oxygen species
  RV = rapid ventricular
  RyR = ryanodine receptor
  SIN-1 = 3-morpholinosydnonimine
  SR = sarcoplasmic reticulum







HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.